New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:32 EDTNVIVInvivo announces BNI as third clinical trial site for neuro-spinal scaffold
InVivo Therapeutics Holdings announced that a third clinical site, the Barrow Neurological Institute, or BNI, in Phoenix, AZ, is now open for enrollment for patients with acute spinal cord injury. The first clinical site, The University of Arizona Medical Center in Tucson, AZ, was approved in April of this year under the direction of Principal Investigator Ali A. Baaj, MD, Assistant Professor of Surgery and Director, Spinal Neurosurgery Program at The University of Arizona Medical Center. A second clinical site, the Carolina Medical Center in Charlotte, NC, opened for enrollment in May of this year. Dom Coric, MD, of Carolina Neurosurgery & Spine Associates, Chief of Neurosurgery at Carolinas Medical Center, and William L. Bockenek, MD, head of Carolinas Rehabilitation, Charlotte, are Co-Principal Investigators. This is the company’s first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold. The pilot study has been approved by the FDAand is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. InVivo then expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption.
News For NVIV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
08:01 EDTNVIVInvivo Therapeutics raises $12M in a registered direct offering
Subscribe for More Information
January 22, 2015
08:11 EDTNVIVInvivo Therapeutics announces enrollment of second subject in pilot study
Subscribe for More Information
January 21, 2015
08:08 EDTNVIVInvivo Therapeutics announces three-month update for neuro-spinal scaffold trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use